Renalytix Plc
$0.32
24H
Market Cap
Volume
Supply
Price Chart
About Renalytix Plc - RENX.L
Renalytix Plc is a company that specializes in the development of artificial intelligence-enabled clinical diagnostics for kidney disease. Their mission is to improve the outcomes and reduce the costs of kidney disease in at-risk patients through their diagnostic solutions.
What are Renalytix Plc's core values and mission statement?
Renalytix Plc's mission is typically centered around advancing kidney disease diagnosis and prognosis through their artificial intelligence-enabled clinical in vitro diagnostics. Their core values often focus on innovation, patient care, accuracy, and collaboration with healthcare professionals to improve outcomes for individuals with kidney disease.
Who founded Renalytix Plc and when?
Renalytix Plc, a company specializing in artificial intelligence-enabled diagnostics for kidney disease, was founded by James McCullough and Michael Donovan in July 2018.
Who leads Renalytix Plc?
As of my last update, James McCullough serves as the CEO of Renalytix Plc.
Where is Renalytix Plc located, and what is its base country?
Renalytix Plc is headquartered in Cardiff, United Kingdom, which is also its base country.
On which exchanges is Renalytix Plc traded?
Renalytix Plc is traded on the NASDAQ under the ticker symbol RNLX and on the London Stock Exchange (LSE) under the ticker symbol RENX.
Historical data
Renalytix Plc (RENX) Price Live Data
The live price of Renalytix Plc (RENX) is $0.32, with a trading volume of 86,421 in the last 24 hours. Wrapstocks updates the RENX price in real-time. Renalytix Plc is down -3.73% in the last 24 hours. The company has a live market cap of $403,771.35 and a supply of 1,262,190 RENX stocks.
Renalytix Plc (RENX) is traded on London Stock Exchange, and currently, the market is closed; trading will be resumed in 14 hours and 26 minutes.
